12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tergenpumatucel-L: Phase IIb/III started

NewLink began an open-label Phase IIb/III trial to compare 2 dosing schedules of tergenpumatucel-L at 300 million cells via intradermal injections vs. 75 mg/m 2 IV docetaxel every 3 weeks for 4 doses in about 240 patients with progressive or relapsed...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >